BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38361314)

  • 21. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.
    El-Azony A; Basha MAA; Almalki YE; Abdelmaksoud B; Hefzi N; Alnagar AA; Mahdey S; Ali IM; Nasr I; Abdalla AAEM; Yousef HY; Zaitoun MMA; Elsayed SB; Nada MG; Amin MI; Hassan RM; Ali SA; Dawoud TM; Aly SA; Algazzar YH; Abdelhamed H
    Eur Radiol; 2024 Apr; 34(4):2500-2511. PubMed ID: 37812294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
    Cerci JJ; Györke T; Fanti S; Paez D; Meneghetti JC; Redondo F; Celli M; Auewarakul C; Rangarajan V; Gujral S; Gorospe C; Campo MV; Chung JK; Morris TP; Dondi M; Carr R;
    J Nucl Med; 2014 Oct; 55(10):1591-7. PubMed ID: 25214642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Skeletal Radiol; 2015 May; 44(5):687-94. PubMed ID: 25662178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology.
    Martín-Moro F; Piris-Villaespesa M; Marquet-Palomanes J; García-Cosío M; Villarrubia J; Lario A; García I; Michael B; Roldán E; García-Vela JA; Lopez-Jiménez J
    Cytometry B Clin Cytom; 2020 Nov; 98(6):525-528. PubMed ID: 31873987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre
    Doma A; Zevnik K; Studen A; Prevodnik VK; Gasljevic G; Novakovic BJ
    Radiol Oncol; 2024 Mar; 58(1):15-22. PubMed ID: 38378029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
    Campbell J; Seymour JF; Matthews J; Wolf M; Stone J; Juneja S
    Eur J Haematol; 2006 Jun; 76(6):473-80. PubMed ID: 16529599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma.
    Terziev D; Bauer M; Paschold L; Wickenhauser C; Wienke A; Binder M; Müller LP; Weber T
    PLoS One; 2020; 15(7):e0235786. PubMed ID: 32639975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings.
    Sovani V; Harvey C; Haynes AP; McMillan AK; Clark DM; O'Connor SR
    J Clin Pathol; 2014 May; 67(5):389-95. PubMed ID: 24327662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumors of lymphoid and hematopoietic tissue of spleen: a clinicopathologic analysis of 53 cases].
    Chen DB; Shen DH; Zhang H; Wang Y; Song QJ; Yang SM; Fang XZ
    Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):775-781. PubMed ID: 29136691
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical Significance of Bone Marrow Involvement as Confirmed by Bone Marrow Aspiration vs. Bone Marrow Biopsy in Diffuse Large B-cell Lymphoma.
    Hantaweepant C; Chinthammitr Y; Khuhapinant A; Sukpanichnant S
    J Med Assoc Thai; 2016 Mar; 99(3):262-9. PubMed ID: 27276736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
    Tadmor T; Shvidel L; Aviv A; Ruchlemer R; Bairey O; Yuklea M; Herishanu Y; Braester A; Rahimi-Levene N; Vernea F; Ben-Ezra J; Bejar J; Polliack A;
    Cancer; 2013 May; 119(10):1853-9. PubMed ID: 23423815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.
    Rijal S; Kok J; Coombes C; Smyth L; Hourigan J; Jain S; Talaulikar D
    BMC Cancer; 2020 Nov; 20(1):1061. PubMed ID: 33143694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.